LetibotulinumtoxinA-wlbg (Letybo, Hugel & Benev) is now fully commercialized in the U.S.
“We are honored to join forces with Hugel to bring Letybo to the U.S. market,” says Ethan Min, Chief Executive Officer at BENEV, in a news release. “This partnership with Hugel allows us to strengthen our market position and fulfill our mission to BENefit EVeryone through transformative aesthetic solutions.”
LetibotulinumtoxinA is the No. 1 neuromodulator in South Korea. It’s approved in over 65 countries and the sixth neuromodulator to receive approval by the U.S. Food and Drug Administration. It is approved for the temporary improvement of moderate to severe glabellar lines in adults.
